Efficacy of canakinumab in mild or severe COVID-19 pneumonia.
Identifieur interne : 000520 ( Main/Exploration ); précédent : 000519; suivant : 000521Efficacy of canakinumab in mild or severe COVID-19 pneumonia.
Auteurs : Falasca Katia [Italie] ; Di Penta Myriam [Italie] ; Claudio Ucciferri [Italie] ; Antonio Auricchio [Italie] ; Marta Di Nicola [Italie] ; Michele Marchioni [Italie] ; Celletti Eleonora [Italie] ; Sabatini Emanuela [Italie] ; Francesco Cipollone [Italie] ; Jacopo Vecchiet [Italie]Source :
- Immunity, inflammation and disease [ 2050-4527 ] ; 2021.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Anticorps monoclonaux humanisés (usage thérapeutique), Antiviraux (usage thérapeutique), Association de médicaments (MeSH), Association thérapeutique (MeSH), Femelle (MeSH), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Interleukine-1 bêta (antagonistes et inhibiteurs), Lopinavir (usage thérapeutique), Mâle (MeSH), Oxygénothérapie (MeSH), Pandémies (MeSH), Ritonavir (usage thérapeutique), Résultat thérapeutique (MeSH), Sujet âgé (MeSH), Thérapie moléculaire ciblée (MeSH).
- MESH :
- antagonistes et inhibiteurs : Interleukine-1 bêta.
- usage thérapeutique : Anticorps monoclonaux humanisés, Antiviraux, Hydroxychloroquine, Lopinavir, Ritonavir.
- Adulte d'âge moyen, Association de médicaments, Association thérapeutique, Femelle, Humains, Mâle, Oxygénothérapie, Pandémies, Résultat thérapeutique, Sujet âgé, Thérapie moléculaire ciblée.
English descriptors
- KwdEn :
- Aged (MeSH), Antibodies, Monoclonal, Humanized (therapeutic use), Antiviral Agents (therapeutic use), COVID-19 (blood), COVID-19 (drug therapy), COVID-19 (therapy), Combined Modality Therapy (MeSH), Drug Therapy, Combination (MeSH), Female (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Interleukin-1beta (antagonists & inhibitors), Lopinavir (therapeutic use), Male (MeSH), Middle Aged (MeSH), Molecular Targeted Therapy (MeSH), Oxygen Inhalation Therapy (MeSH), Pandemics (MeSH), Ritonavir (therapeutic use), SARS-CoV-2 (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , antagonists & inhibitors : Interleukin-1beta.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized, Antiviral Agents, Hydroxychloroquine, Lopinavir, Ritonavir.
- blood : COVID-19.
- drug therapy : COVID-19.
- therapy : COVID-19.
- Aged, Combined Modality Therapy, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Molecular Targeted Therapy, Oxygen Inhalation Therapy, Pandemics, SARS-CoV-2, Treatment Outcome.
Abstract
BACKGROUND
Clinicians all around the world are currently experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several therapeutic strategies have been used until now but, to date, there is no specific therapy to treat SARS-CoV-2 infection. In this study, we used canakinumab, a human monoclonal antibody targeting interleukin-1 beta to improve respiratory function and laboratory parameters compared with standard therapy (hydroxycloroquine plus lopinavir/ritonavir).
METHODS
We enrolled 34 patients with mild or severe non intensive care unit (ICU) coronavirus disease 2019 (COVID-19): 17 patients treated with standard therapy and 17 patients treated with a subcutaneous single dose of canakinumab 300 mg. We collected data about oxygen supports and laboratory parameters such as inflammation indices and hemogasanalysis. We compared the data collected before the administration of canakinumab (T0), 3 days after T0 (T1) and 7 days after T0 (T2) with the same data from patients taking the standard therapy.
RESULTS
We observed a reduction in inflammation indices and a significant and rapid increase in P/F ratio in canakinumab group, with improvement of 60.3% after the administration. We reported a significant reduction in oxygen flow in patients treated with canakinumab (-28.6% at T1 vs. T0 and -40.0% at T2 vs. T1). Conversely, the standard group increased the supply of high oxygen at T1 versus T0 (+66.7%), but reduced oxygen flows at T2 versus T1 (-40.0%).
CONCLUSION
In hospitalized adult patients with mild or severe non ICU COVID-19, canakinumab could be a valid therapeutic option. Canakinumab therapy causes rapid and long-lasting improvement in oxygenation levels in the absence of any severe adverse events.
DOI: 10.1002/iid3.400
PubMed: 33465283
PubMed Central: PMC8013503
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of canakinumab in mild or severe COVID-19 pneumonia.</title><author><name sortKey="Katia, Falasca" sort="Katia, Falasca" uniqKey="Katia F" first="Falasca" last="Katia">Falasca Katia</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Myriam, Di Penta" sort="Myriam, Di Penta" uniqKey="Myriam D" first="Di Penta" last="Myriam">Di Penta Myriam</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Ucciferri, Claudio" sort="Ucciferri, Claudio" uniqKey="Ucciferri C" first="Claudio" last="Ucciferri">Claudio Ucciferri</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Health Sciences, University of Molise, Campobasso</wicri:regionArea><wicri:noRegion>Campobasso</wicri:noRegion></affiliation></author><author><name sortKey="Auricchio, Antonio" sort="Auricchio, Antonio" uniqKey="Auricchio A" first="Antonio" last="Auricchio">Antonio Auricchio</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Di Nicola, Marta" sort="Di Nicola, Marta" uniqKey="Di Nicola M" first="Marta" last="Di Nicola">Marta Di Nicola</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. d'Annunzio University of Chieti, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. d'Annunzio University of Chieti, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Marchioni, Michele" sort="Marchioni, Michele" uniqKey="Marchioni M" first="Michele" last="Marchioni">Michele Marchioni</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. d'Annunzio University of Chieti, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. d'Annunzio University of Chieti, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Eleonora, Celletti" sort="Eleonora, Celletti" uniqKey="Eleonora C" first="Celletti" last="Eleonora">Celletti Eleonora</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Emanuela, Sabatini" sort="Emanuela, Sabatini" uniqKey="Emanuela S" first="Sabatini" last="Emanuela">Sabatini Emanuela</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Cipollone, Francesco" sort="Cipollone, Francesco" uniqKey="Cipollone F" first="Francesco" last="Cipollone">Francesco Cipollone</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Vecchiet, Jacopo" sort="Vecchiet, Jacopo" uniqKey="Vecchiet J" first="Jacopo" last="Vecchiet">Jacopo Vecchiet</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33465283</idno><idno type="pmid">33465283</idno><idno type="doi">10.1002/iid3.400</idno><idno type="pmc">PMC8013503</idno><idno type="wicri:Area/Main/Corpus">000466</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000466</idno><idno type="wicri:Area/Main/Curation">000466</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000466</idno><idno type="wicri:Area/Main/Exploration">000466</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy of canakinumab in mild or severe COVID-19 pneumonia.</title><author><name sortKey="Katia, Falasca" sort="Katia, Falasca" uniqKey="Katia F" first="Falasca" last="Katia">Falasca Katia</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Myriam, Di Penta" sort="Myriam, Di Penta" uniqKey="Myriam D" first="Di Penta" last="Myriam">Di Penta Myriam</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Ucciferri, Claudio" sort="Ucciferri, Claudio" uniqKey="Ucciferri C" first="Claudio" last="Ucciferri">Claudio Ucciferri</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Health Sciences, University of Molise, Campobasso</wicri:regionArea><wicri:noRegion>Campobasso</wicri:noRegion></affiliation></author><author><name sortKey="Auricchio, Antonio" sort="Auricchio, Antonio" uniqKey="Auricchio A" first="Antonio" last="Auricchio">Antonio Auricchio</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Di Nicola, Marta" sort="Di Nicola, Marta" uniqKey="Di Nicola M" first="Marta" last="Di Nicola">Marta Di Nicola</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. d'Annunzio University of Chieti, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. d'Annunzio University of Chieti, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Marchioni, Michele" sort="Marchioni, Michele" uniqKey="Marchioni M" first="Michele" last="Marchioni">Michele Marchioni</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. d'Annunzio University of Chieti, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. d'Annunzio University of Chieti, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Eleonora, Celletti" sort="Eleonora, Celletti" uniqKey="Eleonora C" first="Celletti" last="Eleonora">Celletti Eleonora</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Emanuela, Sabatini" sort="Emanuela, Sabatini" uniqKey="Emanuela S" first="Sabatini" last="Emanuela">Sabatini Emanuela</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Cipollone, Francesco" sort="Cipollone, Francesco" uniqKey="Cipollone F" first="Francesco" last="Cipollone">Francesco Cipollone</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author><author><name sortKey="Vecchiet, Jacopo" sort="Vecchiet, Jacopo" uniqKey="Vecchiet J" first="Jacopo" last="Vecchiet">Jacopo Vecchiet</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti</wicri:regionArea><wicri:noRegion>Chieti</wicri:noRegion></affiliation></author></analytic><series><title level="j">Immunity, inflammation and disease</title><idno type="eISSN">2050-4527</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>COVID-19 (blood)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (therapy)</term><term>Combined Modality Therapy (MeSH)</term><term>Drug Therapy, Combination (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Interleukin-1beta (antagonists & inhibitors)</term><term>Lopinavir (therapeutic use)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Molecular Targeted Therapy (MeSH)</term><term>Oxygen Inhalation Therapy (MeSH)</term><term>Pandemics (MeSH)</term><term>Ritonavir (therapeutic use)</term><term>SARS-CoV-2 (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Association de médicaments (MeSH)</term><term>Association thérapeutique (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Interleukine-1 bêta (antagonistes et inhibiteurs)</term><term>Lopinavir (usage thérapeutique)</term><term>Mâle (MeSH)</term><term>Oxygénothérapie (MeSH)</term><term>Pandémies (MeSH)</term><term>Ritonavir (usage thérapeutique)</term><term>Résultat thérapeutique (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Thérapie moléculaire ciblée (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Interleukin-1beta</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term><term>Antiviral Agents</term><term>Hydroxychloroquine</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Interleukine-1 bêta</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antiviraux</term><term>Hydroxychloroquine</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Combined Modality Therapy</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Molecular Targeted Therapy</term><term>Oxygen Inhalation Therapy</term><term>Pandemics</term><term>SARS-CoV-2</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Association de médicaments</term><term>Association thérapeutique</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Oxygénothérapie</term><term>Pandémies</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Thérapie moléculaire ciblée</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Clinicians all around the world are currently experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several therapeutic strategies have been used until now but, to date, there is no specific therapy to treat SARS-CoV-2 infection. In this study, we used canakinumab, a human monoclonal antibody targeting interleukin-1 beta to improve respiratory function and laboratory parameters compared with standard therapy (hydroxycloroquine plus lopinavir/ritonavir).</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We enrolled 34 patients with mild or severe non intensive care unit (ICU) coronavirus disease 2019 (COVID-19): 17 patients treated with standard therapy and 17 patients treated with a subcutaneous single dose of canakinumab 300 mg. We collected data about oxygen supports and laboratory parameters such as inflammation indices and hemogasanalysis. We compared the data collected before the administration of canakinumab (T0), 3 days after T0 (T1) and 7 days after T0 (T2) with the same data from patients taking the standard therapy.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>We observed a reduction in inflammation indices and a significant and rapid increase in P/F ratio in canakinumab group, with improvement of 60.3% after the administration. We reported a significant reduction in oxygen flow in patients treated with canakinumab (-28.6% at T1 vs. T0 and -40.0% at T2 vs. T1). Conversely, the standard group increased the supply of high oxygen at T1 versus T0 (+66.7%), but reduced oxygen flows at T2 versus T1 (-40.0%).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>In hospitalized adult patients with mild or severe non ICU COVID-19, canakinumab could be a valid therapeutic option. Canakinumab therapy causes rapid and long-lasting improvement in oxygenation levels in the absence of any severe adverse events.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33465283</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2050-4527</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>06</Month></PubDate></JournalIssue><Title>Immunity, inflammation and disease</Title><ISOAbbreviation>Immun Inflamm Dis</ISOAbbreviation></Journal><ArticleTitle>Efficacy of canakinumab in mild or severe COVID-19 pneumonia.</ArticleTitle><Pagination><MedlinePgn>399-405</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/iid3.400</ELocationID><Abstract><AbstractText Label="BACKGROUND">Clinicians all around the world are currently experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several therapeutic strategies have been used until now but, to date, there is no specific therapy to treat SARS-CoV-2 infection. In this study, we used canakinumab, a human monoclonal antibody targeting interleukin-1 beta to improve respiratory function and laboratory parameters compared with standard therapy (hydroxycloroquine plus lopinavir/ritonavir).</AbstractText><AbstractText Label="METHODS">We enrolled 34 patients with mild or severe non intensive care unit (ICU) coronavirus disease 2019 (COVID-19): 17 patients treated with standard therapy and 17 patients treated with a subcutaneous single dose of canakinumab 300 mg. We collected data about oxygen supports and laboratory parameters such as inflammation indices and hemogasanalysis. We compared the data collected before the administration of canakinumab (T0), 3 days after T0 (T1) and 7 days after T0 (T2) with the same data from patients taking the standard therapy.</AbstractText><AbstractText Label="RESULTS">We observed a reduction in inflammation indices and a significant and rapid increase in P/F ratio in canakinumab group, with improvement of 60.3% after the administration. We reported a significant reduction in oxygen flow in patients treated with canakinumab (-28.6% at T1 vs. T0 and -40.0% at T2 vs. T1). Conversely, the standard group increased the supply of high oxygen at T1 versus T0 (+66.7%), but reduced oxygen flows at T2 versus T1 (-40.0%).</AbstractText><AbstractText Label="CONCLUSION">In hospitalized adult patients with mild or severe non ICU COVID-19, canakinumab could be a valid therapeutic option. Canakinumab therapy causes rapid and long-lasting improvement in oxygenation levels in the absence of any severe adverse events.</AbstractText><CopyrightInformation>© 2020 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katia</LastName><ForeName>Falasca</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-8795-5410</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myriam</LastName><ForeName>Di Penta</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ucciferri</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5866-3849</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auricchio</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3216-7895</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Nicola</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1748-1931</Identifier><AffiliationInfo><Affiliation>Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. d'Annunzio University of Chieti, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marchioni</LastName><ForeName>Michele</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1702-4127</Identifier><AffiliationInfo><Affiliation>Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, G. d'Annunzio University of Chieti, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eleonora</LastName><ForeName>Celletti</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emanuela</LastName><ForeName>Sabatini</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cipollone</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5993-9341</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Aging Sciences, Internal Medicine, "G. D'Annunzio" University, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vecchiet</LastName><ForeName>Jacopo</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9250-4844</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Science of Aging, Clinic of Infectious Diseases, University "G. d'Annunzio" Chieti-Pescara, Chieti, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immun Inflamm Dis</MedlineTA><NlmUniqueID>101635460</NlmUniqueID><ISSNLinking>2050-4527</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>37CQ2C7X93</RegistryNumber><NameOfSubstance UI="C541220">canakinumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010102" MajorTopicYN="N">Oxygen Inhalation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">IL1-β</Keyword><Keyword MajorTopicYN="Y">SARS COV2</Keyword><Keyword MajorTopicYN="Y">monoclonal antibody</Keyword><Keyword MajorTopicYN="Y">safety</Keyword><Keyword MajorTopicYN="Y">therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>19</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33465283</ArticleId><ArticleId IdType="doi">10.1002/iid3.400</ArticleId><ArticleId IdType="pmc">PMC8013503</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Cheng VCC, Wong SC, Chen JHK, et al. Escalating infection control response to the rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong. Infect Control Hosp Epidemiol. 2020;41(5):493-498.</Citation></Reference><Reference><Citation>Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J Clin Med. 2020;9(4):1225.</Citation></Reference><Reference><Citation>Balachandar V, Mahalaxmi I, Kaavya J, et al. COVID-19: emerging protective measures. Eur Rev Med Pharmacol Sci. 2020;24(6):3422-3425.</Citation></Reference><Reference><Citation>de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523-534.</Citation></Reference><Reference><Citation>Brian DA, Baric RS. Coronavirus genome structure and replication. Curr Top Microbiol Immunol. 2005;287:1-30.</Citation></Reference><Reference><Citation>Barone Mirko UC, Cipollone Giuseppe. Mucilli felice recombinant human angiotensin-converting enzyme 2 and COVID-19 acute respiratory distress syndrome: a theoretical or a real resource? EJMO. 2020;4(2):139-140.</Citation></Reference><Reference><Citation>Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.</Citation></Reference><Reference><Citation>Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-422.</Citation></Reference><Reference><Citation>Rondeau JM, Ramage P, Zurini M, Gram H. The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta. Mabs. 2015;7(6):1151-1160.</Citation></Reference><Reference><Citation>Goldstein H, Browne W, Rasbash J. Multilevel modelling of medical data. Stat Med. 2002;21(21):3291-3315.</Citation></Reference><Reference><Citation>Abbate A, Toldo S, Marchetti C, Kron J, Van Tassell BW, Dinarello CA. Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease. Circ Res. 2020;126(9):1260-1280.</Citation></Reference><Reference><Citation>Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612-632.</Citation></Reference><Reference><Citation>Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325-e331.</Citation></Reference><Reference><Citation>Hacihamdioglu DO, Ozen S. Canakinumab induces remission in a patient with resistant familial Mediterranean fever. Rheumatology. 2012;51(6):1041.</Citation></Reference><Reference><Citation>Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131.</Citation></Reference><Reference><Citation>Li Y, Chen M, Cao H, Zhu Y, Zheng J, Zhou H. Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response. Microbes Infect. 2013;15(2):88-95.</Citation></Reference><Reference><Citation>Lau SKP, Lau CCY, Chan KH, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol. 2013;94(Pt 12):2679-2690.</Citation></Reference><Reference><Citation>Ucciferri CAA, Di Nicola M, Potere N, et al. Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatol. 2020;2(8):e457-ee458.</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country></list><tree><country name="Italie"><noRegion><name sortKey="Katia, Falasca" sort="Katia, Falasca" uniqKey="Katia F" first="Falasca" last="Katia">Falasca Katia</name></noRegion><name sortKey="Auricchio, Antonio" sort="Auricchio, Antonio" uniqKey="Auricchio A" first="Antonio" last="Auricchio">Antonio Auricchio</name><name sortKey="Cipollone, Francesco" sort="Cipollone, Francesco" uniqKey="Cipollone F" first="Francesco" last="Cipollone">Francesco Cipollone</name><name sortKey="Di Nicola, Marta" sort="Di Nicola, Marta" uniqKey="Di Nicola M" first="Marta" last="Di Nicola">Marta Di Nicola</name><name sortKey="Eleonora, Celletti" sort="Eleonora, Celletti" uniqKey="Eleonora C" first="Celletti" last="Eleonora">Celletti Eleonora</name><name sortKey="Emanuela, Sabatini" sort="Emanuela, Sabatini" uniqKey="Emanuela S" first="Sabatini" last="Emanuela">Sabatini Emanuela</name><name sortKey="Marchioni, Michele" sort="Marchioni, Michele" uniqKey="Marchioni M" first="Michele" last="Marchioni">Michele Marchioni</name><name sortKey="Myriam, Di Penta" sort="Myriam, Di Penta" uniqKey="Myriam D" first="Di Penta" last="Myriam">Di Penta Myriam</name><name sortKey="Ucciferri, Claudio" sort="Ucciferri, Claudio" uniqKey="Ucciferri C" first="Claudio" last="Ucciferri">Claudio Ucciferri</name><name sortKey="Ucciferri, Claudio" sort="Ucciferri, Claudio" uniqKey="Ucciferri C" first="Claudio" last="Ucciferri">Claudio Ucciferri</name><name sortKey="Vecchiet, Jacopo" sort="Vecchiet, Jacopo" uniqKey="Vecchiet J" first="Jacopo" last="Vecchiet">Jacopo Vecchiet</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000520 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000520 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33465283
|texte= Efficacy of canakinumab in mild or severe COVID-19 pneumonia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33465283" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |